Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 4/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 9/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12284564 | 0.89 | KDM4E (0.59) | MAPK10KDM4EBRD4MAPK8ALDH1A1 | |
| SCHEMBL2417549 | 0.87 | KDM4E (0.48) | MAPK10USP2KDM4EBRD4L3MBTL1 | |
| SCHEMBL12284311 | 0.77 | MAPK8 (0.51) | KDM4EBRD4MAPK8ALDH1A1NR4A2 | |
| SCHEMBL2419642 | 0.76 | LMNA (0.52) | KDM4EBRD4MAPK8RXFP1 | |
| SCHEMBL9974671 | 0.75 | KDM4E (0.59) | MAPK10KDM4EBRD4MAPK8ALDH1A1 | |
| SCHEMBL12284876 | 0.74 | MAPK8 (0.54) | MAPK10USP2MAPK8ALDH1A1MAPK9 | |
| SCHEMBL12284388 | 0.73 | MAPK14 (0.50) | BRD4 | |
| SCHEMBL4711631 | 0.73 | MAPK8 (0.86) | MAPK10MAPK8MAPK9 | |
| SCHEMBL18284179 | 0.71 | CNR1 (0.54) | KDM4EALDH1A1NR4A2 | |
| SCHEMBL29778993 | 0.71 | MAPK8 (0.59) | MAPK10USP2KDM4EMAPK8ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101679275-B | Isocarbostyril derivative and its pharmaceutical uses | ASTRAZENECA AB | 2013-07-31 | — | — | CN | disclosed |
| EP-2144881-B1 | ISOQUINOLINONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE ( COPD ) AND ASTHMA | ASTRAZENECA AB (SE) | 2012-06-20 | — | — | EP | disclosed |
| US-8012979-B2 | Compounds and their uses 707 | ASTRAZENECA AB (SE) | 2011-09-06 | — | — | US | disclosed |
| US-8012979-B2 | Compounds and their uses 707 | ASTRAZENECA AB (SE) | 2011-09-06 | — | — | US | disclosed |
| CN-101679275-A | New compounds 707 and their uses | ASTRAZENECA AB | 2010-03-24 | — | — | CN | disclosed |
| US-20090023746-A1 | COMPOUNDS AND THEIR USES 707 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023746-A1 | COMPOUNDS AND THEIR USES 707 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| WO-2008122765-A1 | NEW COMPOUNDS AND THEIR USES 707 | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023746-A1 | COMPOUNDS AND THEIR USES 707 | CYP3A7, UGT1A7, UGT2B7 | MAPK10 3748/4885USP2 3437/4885KDM4E 2093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.